References
- Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1–15, 71–85
- Valavaara R, Pyrhönen S, Heikkinen M. Toremifene, a new anti-estrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 1988; 24: 785–90
- Jordan VC. Alternate antiestrogens and approaches to the prevention of breast cancer. J Cell Biochem 1995; 22: 51–7
- Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet 1995; 346: 883–7
- McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. Br Med J 1995; 311: 977–80
- Grey AB, Stapleton JP, Evans MC, et al. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995; 80: 3191–5
- Anker G, Lönning PE, Ueland PM, et al. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995; 60: 365–8
- Wild RA. Estrogen: effects on the cardiovascular tree. Obstet Gynecol 1996; 87: 27S–35S
- Gangar KF, Vyas S, Whitehead M, et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 338: 839–42
- Mikkola T, Turunen P, Avela K, et al. 17β-Estradiol stimulates prostacyclin, but not endothelin-1 production in human vascular endothelial cells. J Clin Endocrinol Metab 1995; 80: 1831–6
- Foidart JM, Dombrowitz N, de Lieniere B. Urinary excretion of prostacyclin and thromboxane metabolites in postmenopausal women treated with percutaneous estradiol (Oestrogel®) or conjugated estrogens (Premarin®). Physiological Hormone Replacement Therapy, N Dusitsin, M Notelovitz. Parthenon Publishing, CarnforthUK 1990
- Cicinelli E, Ignarro LJ, Lograno M, et al. Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertil Steril 1997; 6: 63–6
- Wilcox JG, Hatch IE, Gentzschein E, et al. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril 1997; 67: 273–7
- Ylikorkala O, Orpana A, Puolakka J, et al. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab 1995; 80: 3384–7
- Neven P, Shepherd JH, Lowe DG. Tamoxifen and gynaecologist. Br J Obstet Gynaecol 1993; 100: 893–7
- Marttunen MB, Pyrhönen S, Tiitinen AE, et al. Effect of antiestrogen regimen on prostacyclin and thromboxane A2 in postmenopausal patients with breast cancer: evidence of significance of hypertension, smoking or previous use of estrogen therapy. Prostaglandins 1996; 52: 317–26
- Marttunen MB, Hietanen P, Tiitinen A, et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998; 83: 1158–62
- Homesley HD, Shemano I, Gams RG, et al. Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. Am J Clin Oncol 1993; 16: 117–22
- Vane JR, Änggård RM, Botting RM. Regulatory functions of vascular endothelium. N Engl J Med 1990; 323: 27–36
- Luscher TF, Tanner FC, Dohi Y. Age, hypertension, and hypercholesterolaemia alter endothelium-dependent vascular regulation. Pharmacol Toxicol 1992; 70: 32S–39S
- Viinikka L. Nitric oxide as a challenge for the clinical chemistry laboratory. J Clin Lab Invest 1996; 56: 577–81
- Wasserman AE. The nitrite-nitrosamine situation: a review. Food Eng 1978; 50: 110–16
- Evans TG, Rasmussen K, Wiebke G, et al. Nitric oxide synthesis in patients with advanced HIV infection. Clin Exp Immunol 1994; 97: 83–6